Compare AHT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHT | ALLR |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 19.3M |
| IPO Year | 2003 | 2021 |
| Metric | AHT | ALLR |
|---|---|---|
| Price | $2.38 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 140.8K |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $1,502,759,000.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.77 | ★ N/A |
| Revenue Growth | ★ 5.03 | N/A |
| 52 Week Low | $1.74 | $0.77 |
| 52 Week High | $5.00 | $1.84 |
| Indicator | AHT | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 49.12 |
| Support Level | $1.76 | $0.79 |
| Resistance Level | $3.23 | $1.00 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 45.07 | 40.21 |
Ashford Hospitality Trust Inc is a real estate investment trust (REIT) operating in the hotel lodging industry. The company's portfolio consists of upscale and upper upscale full-service hotels, with its investment focused on acquiring and investing in upper upscale full-service hotels in the United States that have revenue per available room (RevPAR) generally less than twice the U.S. national average, through direct real estate ownership as well as equity and debt investments. Its hotel properties are mainly branded under internationally recognized names such as Hilton, Hyatt, Marriott, and InterContinental Hotels Group. It operates through a single reportable business segment, direct hotel investments, which involves owning hotel properties through acquisitions or new development.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.